Guggenheim raised the firm’s price target on Metsera (MTSR) to $62 from $56 and keeps a Buy rating on the shares, telling investors that preliminary 5-week amylin data for the MET-233i monotherapy program exceeded the firm’s expectations. Following the report of the data, the firm is increasing its view of MET-233i odds of success to 65% from 50%, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MTSR:
- Metsera obesity monotherapy data ‘looks competitive,’ says BofA
- Warner Bros. Discovery to split up, Qualcomm buying Alphawave Semi: Morning Buzz
- Morning Movers: Warner Bros. Discovery climbs after plans to separate
- Metsera, Inc. Reports Positive Phase 1 Trial Results
- Metsera announces topline data from Phase 1 trial of MET-233i